167 related articles for article (PubMed ID: 9636477)
1. Importance of degree of eosinophilia in inflammatory infiltrates within renal allografts in the response to immunosuppressive treatment.
Papadimitriou JC; Nogueira J; Fink JC; Klassen DK; Bartlett ST; Weir MR; Drachenberg CB
Transplant Proc; 1998 Jun; 30(4):1181. PubMed ID: 9636477
[No Abstract] [Full Text] [Related]
2. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal.
Cronin DC; Bruce DS; Newell KA; Josephson MA; Millis JM; Piper JB; Ruebe M; Kirby M; Thistlethwaite JR; Woodle ES
Transplant Proc; 1997; 29(1-2):307. PubMed ID: 9123010
[No Abstract] [Full Text] [Related]
3. Predicting factors for long-term results of OKT3 therapy in steroid-resistant acute rejection following cadaveric renal transplantation.
Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
Transplant Proc; 1998 Jun; 30(4):1170-2. PubMed ID: 9636473
[No Abstract] [Full Text] [Related]
4. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
5. Correlation between Banff classification and reversal of acute renal rejection.
Kokado Y; Kyo M; Takahara S; Ichimaru N; Wang JD; Toki K; Miki T; Okuyama A
Transplant Proc; 1998 Nov; 30(7):3064-6. PubMed ID: 9838350
[No Abstract] [Full Text] [Related]
6. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
7. Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept.
Carl S; Dörsam J; Mandelbaum A; Staehler G; Wiesel M
Transplant Proc; 1998 Jun; 30(4):1236-7. PubMed ID: 9636502
[No Abstract] [Full Text] [Related]
8. Graft outcome in patients with biopsy-proven chronic renal allograft rejection.
Peddi VR; Schroeder TJ; Weiskittel P; First MR
Transplant Proc; 1999; 31(1-2):1308-9. PubMed ID: 10083584
[No Abstract] [Full Text] [Related]
9. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
10. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
11. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H
Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320
[No Abstract] [Full Text] [Related]
12. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection.
Gaber LW; Moore LW; Alloway RR; Flax S; Gaber AO
Transplant Proc; 1995 Feb; 27(1):1019. PubMed ID: 7878784
[No Abstract] [Full Text] [Related]
13. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
14. Successful therapy of chronic renal allograft failure by enhanced immunosuppression.
Kliem V; Tiroke T; Ehlerding G; Eberhard O; Behrend M; Frei U; Koch KM; Pichlmayr R; Brunkhorst R
Transplant Proc; 1998 Jun; 30(4):1207-9. PubMed ID: 9636490
[No Abstract] [Full Text] [Related]
15. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
16. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
[No Abstract] [Full Text] [Related]
17. Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.
Park K; Kim SI; Moon JI; Kim YS; Kim MS
Transplant Proc; 1998 Nov; 30(7):3575. PubMed ID: 9838565
[No Abstract] [Full Text] [Related]
18. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
[No Abstract] [Full Text] [Related]
19. Effectiveness of immunosuppressive treatment for recurrent or refractory pancreas allograft rejection: correlation with histologic grade.
Papadimitriou JC; Wiland A; Drachenberg CB; Klassen DK; Bartlett ST
Transplant Proc; 1998 Dec; 30(8):3945. PubMed ID: 9865254
[No Abstract] [Full Text] [Related]
20. Antibody therapy in steroid-resistant rejection.
Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
[No Abstract] [Full Text] [Related]
[Next] [New Search]
